Page of

Oesophageal cancer and dysphagia: Oesophageal cancer and dysphagia Expert commentary David Propper Expert commentary David Propper 

Oesophageal cancer and dysphagia: Oesophageal cancer and dysphagia Expert commentary David Propper Expert commentary David Propper
Chapter:
Oesophageal cancer and dysphagia: Expert commentary David Propper
Source:
Challenging Concepts in Oncology
Author(s):

Marcus Remer

DOI:
10.1093/med/9780199688883.003.0007

The increasing incidence of oesophageal cancer in Western countries has been associated with a rise in adenocarcinoma arising from Barrett’s metaplasia. Tobacco and alcohol consumption remain significant risk factors for cancer development. Fewer than 30% of oesophageal cancers present at a stage suitable for radical therapy. A multidisciplinary multimodality treatment approach has improved survival outcomes for locally advanced disease. The choice and timing of treatments are highly dependent on the tumour stage and histological subtype. Accurate staging is essential to inform management decisions and optimize treatment outcome. The majority of cancers present at an advanced stage, and overall prognosis remains poor; the median overall survival for advanced oesophageal cancer treated with palliative chemotherapy is approximately 11 months. This is the discussion of a case of squamous cancer, treated with chemoradiotherapy (and not surgery), with subsequent progression and metastatic disease.

Sign In

Copyright © 2020. All rights reserved.